131 related articles for article (PubMed ID: 32209841)
1. Evaluation of anti-cancer potency of silibinin on murine renal carcinoma RenCa cells in an animal model with an intact immune system.
Yang C; Li F; Ma J; Zhang HB; Jia J; Zeng J; Wang X; He D; Guo P
Anticancer Drugs; 2020 Sep; 31(8):785-791. PubMed ID: 32209841
[TBL] [Abstract][Full Text] [Related]
2. Silibinin inhibits epithelial‑mesenchymal transition of renal cell carcinoma through autophagy‑dependent Wnt/β‑catenin signaling.
Fan Y; Hou T; Dan W; Liu T; Luan J; Liu B; Li L; Zeng J
Int J Mol Med; 2020 May; 45(5):1341-1350. PubMed ID: 32323735
[TBL] [Abstract][Full Text] [Related]
3. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
5. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Chang HR; Chen PN; Yang SF; Sun YS; Wu SW; Hung TW; Lian JD; Chu SC; Hsieh YS
Mol Carcinog; 2011 Oct; 50(10):811-23. PubMed ID: 21574189
[TBL] [Abstract][Full Text] [Related]
6. 12-O-Tetradecanoyl phorbol-13-acetate (TPA)-induced growth arrest is increased by silibinin by the down-regulation of cyclin B1 and cdc2 and the up-regulation of p21 expression in MDA-MB231 human breast cancer cells.
Kim S; Lee HS; Lee SK; Kim SH; Hur SM; Kim JS; Kim JH; Choe JH; Shin I; Yang JH; Lee JE; Nam SJ
Phytomedicine; 2010 Dec; 17(14):1127-32. PubMed ID: 20554189
[TBL] [Abstract][Full Text] [Related]
7. Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma.
Ma Z; Liu W; Zeng J; Zhou J; Guo P; Xie H; Yang Z; Zheng L; Xu S; Wang X; Chang LS; He D; Li L
Oncol Rep; 2015 Nov; 34(5):2461-8. PubMed ID: 26323996
[TBL] [Abstract][Full Text] [Related]
8. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Yang CY; Tsao CH; Hsieh CC; Lin CK; Lin CS; Li YH; Chang WC; Cheng JC; Lin GJ; Sytwu HK; Wang YL; Chen YW
PLoS One; 2020; 15(7):e0236101. PubMed ID: 32678829
[TBL] [Abstract][Full Text] [Related]
10. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft.
Kaur M; Velmurugan B; Tyagi A; Deep G; Katiyar S; Agarwal C; Agarwal R
Mol Cancer Ther; 2009 Aug; 8(8):2366-74. PubMed ID: 19638451
[TBL] [Abstract][Full Text] [Related]
11. Silibinin Retards Colitis-associated Carcinogenesis by Repression of Cdc25C in Mouse Model.
Li W; Zhao X; Lv X; Han W; Wang H
Inflamm Bowel Dis; 2019 Jun; 25(7):1187-1195. PubMed ID: 30753481
[TBL] [Abstract][Full Text] [Related]
12. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Fan K; Zhou M; Pathak MK; Lindner DJ; Altuntas CZ; Tuohy VK; Borden EC; Yi T
J Immunol; 2005 Nov; 175(10):7003-8. PubMed ID: 16272361
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of urinary bladder cancer cell proliferation by silibinin.
Barros TMB; Lima APB; Almeida TC; da Silva GN
Environ Mol Mutagen; 2020 Apr; 61(4):445-455. PubMed ID: 32078183
[TBL] [Abstract][Full Text] [Related]
14. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Tyagi A; Agarwal C; Harrison G; Glode LM; Agarwal R
Carcinogenesis; 2004 Sep; 25(9):1711-20. PubMed ID: 15117815
[TBL] [Abstract][Full Text] [Related]
15. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation.
Shi Z; Zhou Q; Gao S; Li W; Li X; Liu Z; Jin P; Jiang J
Life Sci; 2019 Jan; 217():70-80. PubMed ID: 30452972
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
17. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
[TBL] [Abstract][Full Text] [Related]
18. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
20. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
